BIM

114.2

+0.79%↑

SRT3

229.2

+0.26%↑

GXI

54

+3.75%↑

ICAD

21.06

-1.5%↓

BIM

114.2

+0.79%↑

SRT3

229.2

+0.26%↑

GXI

54

+3.75%↑

ICAD

21.06

-1.5%↓

BIM

114.2

+0.79%↑

SRT3

229.2

+0.26%↑

GXI

54

+3.75%↑

ICAD

21.06

-1.5%↓

BIM

114.2

+0.79%↑

SRT3

229.2

+0.26%↑

GXI

54

+3.75%↑

ICAD

21.06

-1.5%↓

BIM

114.2

+0.79%↑

SRT3

229.2

+0.26%↑

GXI

54

+3.75%↑

ICAD

21.06

-1.5%↓

Search

Argenx SE

Closed

SectorHealthcare

530.2 1.03

Overview

Share price change

24h

Current

Min

521.4

Max

531.6

Key metrics

By Trading Economics

Income

751M

836M

Sales

730M

1.3B

P/E

Sector Avg

46.72

57.333

EPS

0.72

Profit margin

64.112

Employees

1,599

EBITDA

37M

126M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

-2.07% downside

Dividends

By Dow Jones

Next Earnings

8 maj 2025

Market Stats

By TradingEconomics

Market Cap

-4.3B

32B

Previous open

529.17

Previous close

530.2

Argenx SE Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 kwi 2025, 23:44 UTC

Hot Stocks

Stocks to Watch: Jacobs Solutions, Argenx

10 kwi 2025, 23:39 UTC

Major Market Movers

Argenx ADRs Gain, FDA Approves New Delivery Method of Existing Autoimmune Disease Treatment

Peer Comparison

Price change

Argenx SE Forecast

Price Target

By TipRanks

-2.07% downside

12 Months Forecast

Average 438.33 EUR  -2.07%

High 545 EUR

Low 223 EUR

Based on 6 Wall Street analysts offering 12 month price targets forArgenx SE - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

5

Buy

0

Hold

1

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.